Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pain. -- The two major causes of progression in the SPARC trial - radiologic progression and pain progression - were each associated with a 36% reduction in relative risk of disease progression.

MARTINSRIED/MUNICH, Germany, June 04, 2007 /PRNewswire-FirstCall/ -- Princeton, N.J., and Boulder, CO -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. A New Drug Application (NDA) for satraplatin is currently under priority review by the U.S. Food and Drug Administration (FDA).

"Today hormone-refractory prostate cancer patients whose chemotherapy has failed have no approved treatment options. The data I have presented today from the SPARC trial show that satraplatin lowers the risk of disease progression by 33% compared to control. The data are consistent across numerous pre-defined subsets, including patients previously treated with Taxotere," said Cora Sternberg, M.D., FACP, Chief of the Department of Medical Oncology at the San Camillo and Forlanini Hospitals, Rome, Italy and one of the principal investigators of the SPARC registrational trial. "I believe these efficacy results, together with satraplatin's manageable side e
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:4/27/2015)... Research and Markets ( ... "Endoscopy Global Market - Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market ... 2019 growing at around 7.0% CAGR from 2014 ... growth are aging population, increase in cancer, diabetes, ...
(Date:4/27/2015)... 27, 2015  CytoSorbents Corporation (NASDAQ: CTSO ... its CytoSorb® extracorporeal cytokine adsorber to purify blood ... Dr. Joerg Scheier , M.D. as European ... a specialist in intensive care medicine and anesthesiology, ... in treating critically-ill patients and in the design ...
(Date:4/27/2015)... , April 27, 2015 China Jo-Jo ... " China Jo-Jo "), a leading China-based retail and ... through its online and retail pharmacies, today announced its ... Pharmacy") has signed a new sales incentive agreement with ... in China of Pfizer Inc. ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 2CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 3CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 4CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director 5China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 2China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 3China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer 4
(Date:4/27/2015)... MN (PRWEB) April 27, 2015 Based ... Secura Consultants is one of the few insurance marketing ... in the income and asset protection markets as well ... the industry has afforded Secura Consultants the opportunity to ... to make doing business easier and quicker. , An ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 According to ... and Craniofacial Research), after chronic back pain, TMJ disorders ... resulting in pain and disability. In addition, the report ... percent of the population, costing an estimated 4 billion ... million Americans suffering from seemingly unrelated symptoms such as ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... 2015 TayganPoint Consulting Group, a ... announce their sponsorship of Girls on the Run ... on the Run is a youth development program ... The program is delivered through an interactive curriculum ... to develop the whole girl – physically, mentally, ...
(Date:4/27/2015)... New York, NY (PRWEB) April 27, 2015 ... Jimmy Buffett tickets at the Alpine Valley Music ... in the Elkhart, Wisconsin and Albuquerque, New Mexico area ... in their neck of the woods. Buffett will ... News in Wisconsin. His tour stops during the ...
Breaking Medicine News(10 mins):Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2
... and format for its “OneMedForum 2009” finance ... in San Francisco at the Sir Francis ... and disrupters” affecting each of the following ... System and Neurostimulation; Cardiology; Urology and Sexual ...
... Farms, Inc.,(OTC Bulletin Board: USFM), a diversified commercial ... Network (OTCFN), a division of,National Financial Communications Corp. ... The OTCFN Report details US Farms, Inc.,s current ... growth and,management team. Interested parties can download ...
... Genaera Corporation (Nasdaq: GENR ) today announced ... to present at the 2008 RBC Capital Markets Healthcare Conference. ... discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will ... York on Wednesday, December 11 at 11:00 a.m. ET. , ...
... WASHINGTON, Dec. 4 Stem cells derived from bone marrow ... disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily ... Blood , the official journal of the American Society of ... bullosa is a disorder characterized by extraordinarily fragile skin and ...
... the Nation in Giving as Demand for Nonprofit Services Peaks ... More than half of Coloradans report that they will ... during the economic downturn, according to " Generous Colorado: Why ... which reflects data from surveys conducted October 2008. With demand ...
... Empowerment Fund by purchasing the Green Bracelet at www.simmonsjewelryco.com , ... The Diamond Empowerment Fund (D.E.F.), Hearst Magazines, and ... exclusive "Empowerment for Africa" dinner held at Hearst Tower in ... co-founder Russell Simmons and special guests including ...
Cached Medicine News:Health News: OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 2Health News:OTC Financial Network Issues Corporate Profile on US Farms, Inc. 3Health News:Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 2Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 3Health News:Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder 4Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 2Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 3Health News:Economy Doesn't Dampen Colorado's Giving Spirit According to Statewide Giving and Volunteering Study 4Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: